Literature DB >> 16712637

Social behavior and cortisol reactivity in children with fragile X syndrome.

David Hessl1, Bronwyn Glaser, Jennifer Dyer-Friedman, Allan L Reiss.   

Abstract

OBJECTIVE: To examine the association between limbic-hypothalamic-pituitary-adrenal (L-HPA) axis reactivity and social behavior in children with fragile X syndrome (FXS).
METHOD: Salivary cortisol changes and concurrent anxiety-related behaviors consistent with the behavioral phenotype of FXS were measured in 90 children with the fragile X full mutation and their 90 unaffected siblings during a social challenge task in the home.
RESULTS: Boys and girls with FXS demonstrated more gaze aversion, task avoidance, behavioral signs of distress, and poorer vocal quality than the unaffected siblings. Multiple regression analyses showed that after accounting for effects of IQ, gender, age, quality of the home environment, and basal cortisol level, cortisol reactivity to the task was significantly associated with social gaze in children with FXS. The most gaze-aversive children with FXS had cortisol reductions, whereas those with more eye contact demonstrated the most cortisol reactivity. Unaffected siblings demonstrated an opposite pattern in which less eye contact was associated with increased cortisol reactivity.
CONCLUSIONS: Results of the study suggest a unique relation between abnormal gaze behavior and L-HPA mediated stress reactivity in FXS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712637     DOI: 10.1111/j.1469-7610.2005.01556.x

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  53 in total

Review 1.  Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome.

Authors:  Lawrence K Fung; Allan L Reiss
Journal:  Biol Psychiatry       Date:  2015-12-18       Impact factor: 13.382

2.  Effects of labeling and pointing on object gaze in boys with fragile X syndrome: an eye-tracking study.

Authors:  David P Benjamin; Ann M Mastergeorge; Andrea S McDuffie; Sara T Kover; Randi J Hagerman; Leonard Abbeduto
Journal:  Res Dev Disabil       Date:  2014-07-23

3.  Prevalence and Predictors of Anxiety Disorders in Adolescent and Adult Males with Autism Spectrum Disorder and Fragile X Syndrome.

Authors:  Jordan Ezell; Abigail Hogan; Amanda Fairchild; Kimberly Hills; Jessica Klusek; Leonard Abbeduto; Jane Roberts
Journal:  J Autism Dev Disord       Date:  2019-03

4.  Biobehavioral indicators of social fear in young children with fragile X syndrome.

Authors:  Bridgette L Tonnsen; Svetlana V Shinkareva; Sara C Deal; Deborah D Hatton; Jane E Roberts
Journal:  Am J Intellect Dev Disabil       Date:  2013-11

5.  Emotion potentiated startle in fragile X syndrome.

Authors:  Elizabeth C Ballinger; Lisa Cordeiro; Alyssa D Chavez; Randi J Hagerman; David Hessl
Journal:  J Autism Dev Disord       Date:  2014-10

Review 6.  Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies.

Authors:  Amy A Lightbody; Allan L Reiss
Journal:  Dev Disabil Res Rev       Date:  2009

7.  A Behavioural Assessment of Social Anxiety and Social Motivation in Fragile X, Cornelia de Lange and Rubinstein-Taybi Syndromes.

Authors:  Hayley Crawford; Joanna Moss; Laura Groves; Robyn Dowlen; Lisa Nelson; Donna Reid; Chris Oliver
Journal:  J Autism Dev Disord       Date:  2020-01

Review 8.  Autism-lessons from the X chromosome.

Authors:  Elysa J Marco; David H Skuse
Journal:  Soc Cogn Affect Neurosci       Date:  2006-12       Impact factor: 3.436

9.  Behavioral Markers of Emergent Stranger Anxiety in Infants and Toddlers with Fragile X Syndrome.

Authors:  Bridgette Tonnsen; Jessica Scherr; Debra Reisinger; Jane Roberts
Journal:  J Autism Dev Disord       Date:  2017-11

10.  Aberrant face and gaze habituation in fragile x syndrome.

Authors:  Jennifer Lynn Bruno; Amy S Garrett; Eve-Marie Quintin; Paul K Mazaika; Allan L Reiss
Journal:  Am J Psychiatry       Date:  2014-10       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.